Get the Stockscreener App
9.42
3.40%
0.31
10 X Genomics Inc stock is traded at $9.42, with a volume of 5.02M.
It is up +3.40% in the last 24 hours and up +16.30% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$9.11
Open:
$9.38
24h Volume:
5.02M
Relative Volume:
1.39
Market Cap:
$1.17B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-4.6634
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
-1.15%
1M Performance:
+16.30%
6M Performance:
-40.64%
1Y Performance:
-58.19%
1-Day Range:
$9.21
$9.83
1-Week Range:
$8.945
$9.83
52-Week Range:
$6.78
$24.76
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
9.42 | 1.17B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
285.36 | 45.71B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
62.07 | 9.42B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
58.85 | 9.78B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
111.55 | 8.70B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
41.16 | 6.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
Forecasting The Future: 7 Analyst Projections For 10x Genomics - Benzinga
Long Read Sequencing Market Key Players Analysis10X Genomics, - openPR.com
10x Genomics, Inc. (NASDAQ:TXG) Stock Holdings Increased by Deutsche Bank AG - Defense World
ARK Investment Acquires 290K Shares of 10x Genomics (TXG) | TXG Stock News - GuruFocus
10x Genomics, Inc. (TXG) Stock Analysis: Evaluating the 31.90% Potential Upside - DirectorsTalk Interviews
Cathie Wood's ARK Investment Acquires Significant Stake in 10x G - GuruFocus
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
10 Best Healthcare Stocks to Invest In (June 2025) - Securities.io
ARK Investment Acquires 342K Shares of 10x Genomics (TXG) | TXG Stock News - GuruFocus
Cetera Investment Advisers Raises Stake in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com
10x Genomics, Inc. (NASDAQ:TXG) Given Average Recommendation of “Hold” by Analysts - Defense World
Powell, Mayville Engineering, Graham Corporation, Hyster-Yale Materials Handling, and 10x Genomics Shares Skyrocket, What You Need To Know - Yahoo Finance
Shareholders May Be Wary Of Increasing 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation Package - simplywall.st
10x Genomics, Inc. (TXG) Stock Analysis: A 52.56% Potential Upside Amidst a Challenging Market - DirectorsTalk Interviews
10x Genomics’ (TXG) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Bank of America Corp DE - Defense World
Why 10x Genomics Stock Was Sliding This Week - Barchart.com
10x Genomics Reports Third Quarter 2023 Financial Results - Seeking Alpha
10x Genomics Reports First Quarter 2024 Financial Results - Seeking Alpha
Gotham Asset Management LLC Takes $264,000 Position in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
10x Genomics (NASDAQ:TXG) Price Target Lowered to $18.00 at Morgan Stanley - Defense World
10x Genomics (NASDAQ:TXG) Shares Down 4.8% Following Analyst Downgrade - Defense World
High-Throughput Transcriptomics 2025–2028: Next-Gen Breakthroughs Set to Disrupt Genomics Market - macnifico.pt
10x Genomics (TXG) Price Target Lowered by Morgan Stanley | TXG Stock News - GuruFocus
10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Northern Trust Corp - Defense World
Stephens Reaffirms Overweight Rating for 10x Genomics (NASDAQ:TXG) - Defense World
'Shooting ourselves in the foot': Trump administration cuts force East Bay’s 10x Genomics into layoffs - The Business Journals
Dimensional Fund Advisors LP Sells 23,956 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
NanoString to pay 10x Genomics $68m in global settlement - Life Sciences Intellectual Property Review
10x Genomics reaches settlement with Bruker - Medical Buyer
Stifel Financial Corp Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
UBS Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $12.00 - Defense World
10x Genomics Reaches $68 Million Patent Settlement With Bruker - marketscreener.com
10x Genomics Settles Litigation with Bruker Corporation - TipRanks
10x Genomics settles patent dispute with Bruker for $68 million - Investing.com
10x Genomics Announces Patent Litigation Settlement Agreement with Bruker - Financial Times
All Ongoing Lawsuits Between Bruker And 10X Genomics To Be Withdrawn - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96 - simplywall.st
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Chal - GuruFocus
Bruker and 10x Genomics settle patent dispute - Yahoo Finance
10x Genomics, Bruker Strike Deal After $31M Patent Verdict - Law360
10x Genomics (TXG) Sees Price Target Lowered by UBS | TXG Stock News - GuruFocus
UPC battle between 10x Genomics and Curio Bioscience moves to next stage - JUVE Patent
UBS Adjusts Price Target on 10x Genomics to $12 From $14, Maintains Neutral Rating - marketscreener.com
Canaccord Adjusts 10x Genomics (TXG) Price Target Citing Market Uncertainty | TXG Stock News - GuruFocus
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Challenges | TXG Stock News - GuruFocus
10x Genomics (NASDAQ:TXG) Price Target Lowered to $6.50 at The Goldman Sachs Group - Defense World
10x Genomics (NASDAQ:TXG) Price Target Cut to $15.00 by Analysts at Canaccord Genuity Group - Defense World
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
10 X Genomics Inc Stock (TXG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hindson Benjamin J. | See Remarks |
May 22 '25 |
Sale |
8.30 |
7,485 |
62,120 |
448,374 |
| Taich Adam | Chief Financial Officer |
May 22 '25 |
Sale |
8.30 |
4,044 |
33,562 |
331,588 |
0.51%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):